RCT | Etrasimod outperforms placebo in ulcerative colitis induction & maintenance

Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies – The Lancet

Commentary on Twitter

Just published @TheLancet – Sandborn et al – Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies https://t.co/BVDWtESWLP#gitwitter #ibd #ulcerativecolitis #ECCO23 #ECCO2023 pic.twitter.com/hjyJ0tdtWd

— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) March 3, 2023